14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ABUS ranks #17374 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Arbutus Biopharma Corporation Stock Forecast NASDAQ:ABUS

$2.68 (-4.63%)

Volume: 5M

Closed: Jan 21, 2022

Hollow Logo Score: -4.781

Arbutus Biopharma Corporation Stock Forecast

$2.68 (-4.63%)

Volume: 5M

Closed: Jan 21, 2022

Score Hollow Logo -4.781

Arbutus Biopharma Corporation Company Profile

100-8900 Glenlyon Parkway

Burnaby BC V5J 5J8



Industry: Biotechnology

Sector: Healthcare

Arbutus Biopharma Corporation


Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). Its lead candidate is ARB-1467, a multi-component RNAi therapeutic product that is designed for the elimination of HBV surface antigen expression in patients chronically infected with HBV. Its HBV product candidates also comprise ARB-1740, a RNAi HBV candidate that is in preclinical studies; small molecule cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; HBV core protein assembly inhibitors; ARB-1598, a toll-like receptor; surface antigen secretion inhibitors; cccDNA epigenetic modifiers; stimulator of interferon genes agonists; and cyclophilin inhibitor drug candidates, including OCB-030 and other cyclophilin inhibitors. In addition, it develops TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02,whichis in Phase III clinical study, a therapeutic targeting transthyretin mediated amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for treating Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE